Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
Tactile Systems Technology (NASDAQ: TCMD) reported Q2 2025 financial results with total revenue increasing 7.8% year-over-year to $78.9 million. The company achieved a gross margin of 75% and net income of $3.2 million, compared to $4.3 million in Q2 2024.
Key highlights include a 52% increase in airway clearance product sales and a 2% increase in lymphedema product line revenue. The company completed its $30 million share repurchase program, with $16.5 million repurchased in Q2. Management updated 2025 guidance, now expecting full-year revenue of $310-315 million and adjusted EBITDA of $33-35 million.
Tactile Systems Technology (NASDAQ: TCMD) ha riportato i risultati finanziari del secondo trimestre 2025 con un fatturato totale in aumento del 7,8% rispetto all'anno precedente, raggiungendo 78,9 milioni di dollari. L'azienda ha ottenuto un margine lordo del 75% e un utile netto di 3,2 milioni di dollari, rispetto ai 4,3 milioni di dollari del secondo trimestre 2024.
Tra i punti salienti si evidenzia un incremento del 52% nelle vendite dei prodotti per la clearance delle vie aeree e un aumento del 2% del fatturato della linea di prodotti per il linfedema. L'azienda ha completato il suo programma di riacquisto azionario da 30 milioni di dollari, con 16,5 milioni di dollari riacquistati nel secondo trimestre. La direzione ha aggiornato le previsioni per il 2025, prevedendo ora un fatturato annuo compreso tra 310 e 315 milioni di dollari e un EBITDA rettificato tra 33 e 35 milioni di dollari.
Tactile Systems Technology (NASDAQ: TCMD) informó los resultados financieros del segundo trimestre de 2025 con un ingreso total que aumentó un 7,8% interanual, alcanzando los 78,9 millones de dólares. La empresa logró un margen bruto del 75% y un ingreso neto de 3,2 millones de dólares, en comparación con 4,3 millones en el segundo trimestre de 2024.
Los aspectos destacados incluyen un aumento del 52% en las ventas de productos para la limpieza de las vías respiratorias y un incremento del 2% en los ingresos de la línea de productos para linfedema. La compañía completó su programa de recompra de acciones por 30 millones de dólares, con 16,5 millones recomprados en el segundo trimestre. La dirección actualizó las previsiones para 2025, esperando ahora ingresos anuales de 310-315 millones de dólares y un EBITDA ajustado de 33-35 millones de dólares.
Tactile Systems Technology (NASDAQ: TCMD)는 2025년 2분기 재무 실적을 발표하며 총 매출이 전년 동기 대비 7.8% 증가한 7,890만 달러를 기록했습니다. 회사는 매출총이익률 75%와 순이익 320만 달러를 달성했으며, 이는 2024년 2분기의 430만 달러와 비교됩니다.
주요 내용으로는 기도 청소 제품 매출이 52% 증가했고, 림프부종 제품 라인 매출이 2% 증가했습니다. 회사는 3,000만 달러 규모의 자사주 매입 프로그램을 완료했으며, 2분기에 1,650만 달러를 매입했습니다. 경영진은 2025년 가이던스를 업데이트하여 연간 매출을 3억 1,000만~3억 1,500만 달러, 조정 EBITDA를 3,300만~3,500만 달러로 예상하고 있습니다.
Tactile Systems Technology (NASDAQ : TCMD) a publié ses résultats financiers du deuxième trimestre 2025 avec un chiffre d'affaires total en hausse de 7,8 % en glissement annuel, atteignant 78,9 millions de dollars. La société a réalisé une marge brute de 75 % et un bénéfice net de 3,2 millions de dollars, contre 4,3 millions au deuxième trimestre 2024.
Les points clés incluent une augmentation de 52 % des ventes de produits pour le dégagement des voies respiratoires et une hausse de 2 % du chiffre d'affaires de la ligne de produits pour le lymphœdème. L'entreprise a achevé son programme de rachat d'actions de 30 millions de dollars, avec 16,5 millions rachetés au deuxième trimestre. La direction a mis à jour ses prévisions pour 2025, prévoyant désormais un chiffre d'affaires annuel de 310 à 315 millions de dollars et un EBITDA ajusté de 33 à 35 millions de dollars.
Tactile Systems Technology (NASDAQ: TCMD) meldete die Finanzergebnisse für das zweite Quartal 2025 mit einem Gesamtumsatzanstieg von 7,8 % im Jahresvergleich auf 78,9 Millionen US-Dollar. Das Unternehmen erzielte eine Bruttomarge von 75 % und einen Nettoertrag von 3,2 Millionen US-Dollar, verglichen mit 4,3 Millionen US-Dollar im zweiten Quartal 2024.
Wichtige Highlights sind ein 52%iger Anstieg der Umsätze mit Produkten zur Atemwegsreinigung sowie ein 2%iger Umsatzanstieg in der Produktlinie für Lymphödem. Das Unternehmen schloss sein 30-Millionen-Dollar-Aktienrückkaufprogramm ab, wobei im zweiten Quartal Aktien im Wert von 16,5 Millionen US-Dollar zurückgekauft wurden. Das Management aktualisierte die Prognose für 2025 und erwartet nun einen Jahresumsatz von 310 bis 315 Millionen US-Dollar und ein bereinigtes EBITDA von 33 bis 35 Millionen US-Dollar.
- Revenue growth of 7.8% year-over-year to $78.9 million
- Airway clearance product line sales increased 52%
- Gross margin improved to 75% from 74% year-over-year
- Completed $30 million share repurchase program
- Increased revolving credit facility capacity from $25M to $40M
- Net income decreased to $3.2M from $4.3M year-over-year
- Adjusted EBITDA declined to $7.7M from $9.1M year-over-year
- Operating expenses increased 13% to $54.7M
- Cash position decreased to $81.5M from $94.4M at year-end 2024
- 2025 adjusted EBITDA guidance of $33-35M below 2024's $37.1M
Insights
Tactile Medical reports 7.8% revenue growth but declining profits amid strategic investments; guidance raised slightly despite margin pressure.
Tactile Medical delivered $78.9 million in Q2 2025 revenue, representing
Despite the revenue beat, profitability metrics showed concerning declines. Net income fell to
Gross margin improved slightly to
The company's balance sheet remains solid with
Management raised the lower end of their 2025 revenue guidance slightly to
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025.
Second Quarter 2025 Summary & Recent Business Highlights:
- Total revenue increased
7.8% year-over-year to$78.9 million - Gross margin of
75% versus74% in Q2 2024 - Net income of
$3.2 million versus$4.3 million in Q2 2024 - Adjusted EBITDA of
$7.7 million versus$9.1 million in Q2 2024 - Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treating patients with head and neck cancer-related lymphedema
- Repurchased
$16.5 million of stock to complete the Company’s share repurchase program
“We delivered strong financial performance in the second quarter, marked by total revenue growth of nearly
“We also remain highly focused on our three strategic priorities for 2025 to improve access to care, expand treatment options for lymphedema patients, and enhance the lifetime patient value. Our key technology and people-related investments are continuing to progress, including strategically expanding our sales force, presenting new clinical data from our head and neck lymphedema trial, growing adoption of Nimbl, and launching pilot programs aimed at simplifying the workflow process of patient identification, referral, and order processing. These priorities are designed to unlock our market opportunity and enable scalable, profitable growth, and we expect to begin benefiting more meaningfully from them in 2026.”
Second Quarter 2025 Financial Results
Total revenue in the second quarter of 2025 increased
Gross profit in the second quarter of 2025 increased
Operating expenses in the second quarter of 2025 increased
Operating income was
Other income was
Income tax expense was
Net income in the second quarter of 2025 was
Weighted average shares used to compute diluted net income per share were 23.2 million and 24.1 million for the second quarters of 2025 and 2024, respectively.
Adjusted EBITDA was
First Six Months 2025 Financial Results
Total revenue for the six months ended June 30, 2025, increased
Net income for the six months ended June 30, 2025, was
Weighted average shares used to compute diluted net income per share were 23.7 million and 24.1 million for the six months ended June 30, 2025 and 2024, respectively.
Adjusted EBITDA was
Balance Sheet Summary
As of June 30, 2025, the Company had
On July 31, 2025, the Company paid the full outstanding principal balance of
2025 Financial Outlook
The Company is updating its 2025 financial outlook and now expects full year 2025 total revenue in the range of
The Company now also expects full year 2025 adjusted EBITDA in the range of
Conference Call
Management will host a conference call with a question-and-answer session at 5:00 p.m. Eastern Time on August 4, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13754589. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.tactilemedical.com.
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13754589. The webcast will be archived at investors.tactilemedical.com.
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements, including guidance for the full year 2025. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; adverse economic conditions, including inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; price increases for supplies and components; wage and component price inflation; loss of a key supplier or other supply chain disruptions; entry of new competitors and/or competitive products; compliance with and changes in federal, state and local government laws and regulations; technological obsolescence of, or quality issues with, the Company’s products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Adjusted EBITDA in this release represents net income (loss), plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense and plus executive transition costs. Reconciliation of this non-GAAP financial measure to its most directly comparable GAAP measure is included in this press release.
This non-GAAP financial measure is presented because the Company believes it is a useful indicator of its operating performance. Management uses this measure principally as a measure of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes this measure is useful to investors as supplemental information and because it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes this non-GAAP financial measure is useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.
The non-GAAP financial measure presented in this release should not be considered as an alternative to, or superior to, its respective GAAP financial measure, as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
| Tactile Systems Technology, Inc. | ||||||
| Condensed Consolidated Balance Sheets | ||||||
| (Unaudited) | ||||||
| June 30, | December 31, | |||||
| (In thousands, except share and per share data) | 2025 | 2024 | ||||
| Assets | ||||||
| Current assets | ||||||
| Cash | $ | 81,528 | $ | 94,367 | ||
| Accounts receivable, net | 33,086 | 44,937 | ||||
| Net investment in leases | 14,457 | 14,540 | ||||
| Inventories | 17,111 | 18,666 | ||||
| Income taxes receivable | 457 | — | ||||
| Prepaid expenses and other current assets | 6,348 | 5,053 | ||||
| Total current assets | 152,987 | 177,563 | ||||
| Non-current assets | ||||||
| Property and equipment, net | 4,897 | 5,603 | ||||
| Right of use operating lease assets | 15,462 | 16,633 | ||||
| Intangible assets, net | 40,904 | 42,789 | ||||
| Goodwill | 31,063 | 31,063 | ||||
| Deferred income taxes | 18,333 | 18,311 | ||||
| Other non-current assets | 9,402 | 5,962 | ||||
| Total non-current assets | 120,061 | 120,361 | ||||
| Total assets | $ | 273,048 | $ | 297,924 | ||
| Liabilities and Stockholders' Equity | ||||||
| Current liabilities | ||||||
| Accounts payable | $ | 8,025 | $ | 5,648 | ||
| Note payable | 2,956 | 2,956 | ||||
| Accrued payroll and related taxes | 12,678 | 17,923 | ||||
| Accrued expenses | 8,180 | 7,780 | ||||
| Income taxes payable | — | 270 | ||||
| Operating lease liabilities | 3,095 | 2,980 | ||||
| Other current liabilities | 5,469 | 3,147 | ||||
| Total current liabilities | 40,403 | 40,704 | ||||
| Non-current liabilities | ||||||
| Note payable, non-current | 21,743 | 23,220 | ||||
| Accrued warranty reserve, non-current | 1,241 | 1,209 | ||||
| Income taxes payable, non-current | 355 | 239 | ||||
| Operating lease liabilities, non-current | 14,380 | 15,955 | ||||
| Total non-current liabilities | 37,719 | 40,623 | ||||
| Total liabilities | 78,122 | 81,327 | ||||
| Stockholders’ equity: | ||||||
| Preferred stock, | — | — | ||||
| Common stock, | 22 | 24 | ||||
| Additional paid-in capital | 158,807 | 180,719 | ||||
| Retained earnings | 36,097 | 35,854 | ||||
| Total stockholders’ equity | 194,926 | 216,597 | ||||
| Total liabilities and stockholders’ equity | $ | 273,048 | $ | 297,924 | ||
| Tactile Systems Technology, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| (In thousands, except share and per share data) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | ||||||||||||||||
| Sales revenue | $ | 70,531 | $ | 64,267 | $ | 123,000 | $ | 117,574 | ||||||||
| Rental revenue | 8,374 | 8,951 | 17,173 | 16,732 | ||||||||||||
| Total revenue | 78,905 | 73,218 | 140,173 | 134,306 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Cost of sales revenue | 17,483 | 16,263 | 31,374 | 31,207 | ||||||||||||
| Cost of rental revenue | 2,629 | 2,852 | 4,660 | 5,567 | ||||||||||||
| Total cost of revenue | 20,112 | 19,115 | 36,034 | 36,774 | ||||||||||||
| Gross profit | ||||||||||||||||
| Gross profit - sales revenue | 53,048 | 48,004 | 91,626 | 86,367 | ||||||||||||
| Gross profit - rental revenue | 5,745 | 6,099 | 12,513 | 11,165 | ||||||||||||
| Gross profit | 58,793 | 54,103 | 104,139 | 97,532 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 30,039 | 28,608 | 57,555 | 55,965 | ||||||||||||
| Research and development | 2,018 | 2,234 | 3,759 | 4,377 | ||||||||||||
| Reimbursement, general and administrative | 22,034 | 16,779 | 42,032 | 33,040 | ||||||||||||
| Intangible asset amortization | 619 | 633 | 1,252 | 1,265 | ||||||||||||
| Total operating expenses | 54,710 | 48,254 | 104,598 | 94,647 | ||||||||||||
| Income (loss) from operations | 4,083 | 5,849 | (459 | ) | 2,885 | |||||||||||
| Interest income | 850 | 754 | 1,745 | 1,467 | ||||||||||||
| Interest expense | (410 | ) | (529 | ) | (834 | ) | (1,096 | ) | ||||||||
| Other income | 1 | — | 1 | 9 | ||||||||||||
| Income before income taxes | 4,524 | 6,074 | 453 | 3,265 | ||||||||||||
| Income tax expense | 1,307 | 1,776 | 210 | 1,176 | ||||||||||||
| Net income | $ | 3,217 | $ | 4,298 | $ | 243 | $ | 2,089 | ||||||||
| Net income per common share | ||||||||||||||||
| Basic | $ | 0.14 | $ | 0.18 | $ | 0.01 | $ | 0.09 | ||||||||
| Diluted | $ | 0.14 | $ | 0.18 | $ | 0.01 | $ | 0.09 | ||||||||
| Weighted-average common shares used to compute net income per common share | ||||||||||||||||
| Basic | 23,092,469 | 23,873,379 | 23,399,848 | 23,769,604 | ||||||||||||
| Diluted | 23,237,671 | 24,099,047 | 23,679,220 | 24,073,986 | ||||||||||||
| Tactile Systems Technology, Inc. | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| Six Months Ended June 30, | ||||||||
| (In thousands) | 2025 | 2024 | ||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 243 | $ | 2,089 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 3,385 | 3,345 | ||||||
| Deferred income taxes | (22 | ) | (30 | ) | ||||
| Stock-based compensation expense | 4,005 | 3,899 | ||||||
| Loss on disposal of property and equipment and intangibles | 68 | 54 | ||||||
| Changes in assets and liabilities, net of acquisition: | ||||||||
| Accounts receivable, net | 11,851 | 1,238 | ||||||
| Net investment in leases | 83 | 644 | ||||||
| Inventories | 1,555 | 3,681 | ||||||
| Income taxes | (611 | ) | (922 | ) | ||||
| Prepaid expenses and other assets | (4,735 | ) | (364 | ) | ||||
| Right of use operating lease assets | (289 | ) | (2 | ) | ||||
| Accounts receivable, non-current | — | 6,425 | ||||||
| Accounts payable | 2,319 | (1,592 | ) | |||||
| Accrued payroll and related taxes | (5,245 | ) | (4,699 | ) | ||||
| Accrued expenses and other liabilities | 2,567 | 300 | ||||||
| Net cash provided by operating activities | 15,174 | 14,066 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (748 | ) | (982 | ) | ||||
| Proceeds from sale of property and equipment | — | 12 | ||||||
| Intangible assets expenditures | (56 | ) | (57 | ) | ||||
| Net cash used in investing activities | (804 | ) | (1,027 | ) | ||||
| Cash flows from financing activities | ||||||||
| Payments on note payable | (1,500 | ) | (1,500 | ) | ||||
| Proceeds from exercise of common stock options | 10 | 2 | ||||||
| Proceeds from the issuance of common stock from the employee stock purchase plan | 843 | 1,044 | ||||||
| Payments for repurchases of common stock | (26,562 | ) | — | |||||
| Net cash used in financing activities | (27,209 | ) | (454 | ) | ||||
| Net (decrease) increase in cash | (12,839 | ) | 12,585 | |||||
| Cash – beginning of period | 94,367 | 61,033 | ||||||
| Cash – end of period | $ | 81,528 | $ | 73,618 | ||||
| Supplemental cash flow disclosure | ||||||||
| Cash paid for interest | $ | 828 | $ | 1,099 | ||||
| Cash paid for taxes | $ | 892 | $ | 2,177 | ||||
| Accrued excise tax on stock repurchases | $ | 210 | $ | — | ||||
| Capital expenditures incurred but not yet paid | $ | 58 | $ | 27 | ||||
The following table summarizes revenue by product line for the three and six months ended June 30, 2025 and 2024:
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue | ||||||||||||||||
| Lymphedema products | $ | 65,969 | $ | 64,683 | $ | 116,524 | $ | 116,996 | ||||||||
| Airway clearance products | 12,936 | 8,535 | 23,649 | 17,310 | ||||||||||||
| Total | $ | 78,905 | $ | 73,218 | $ | 140,173 | $ | 134,306 | ||||||||
| Percentage of total revenue | ||||||||||||||||
| Lymphedema products | 84 | % | 88 | % | 83 | % | 87 | % | ||||||||
| Airway clearance products | 16 | % | 12 | % | 17 | % | 13 | % | ||||||||
| Total | 100 | % | 100 | % | 100 | % | 100 | % | ||||||||
The following table contains a reconciliation of net income to Adjusted EBITDA for the three and six months ended June 30, 2025 and 2024, as well as the dollar and percentage change between the comparable periods:
| Tactile Systems Technology, Inc. | ||||||||||||||||||||||||||||||||
| Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Increase | Six Months Ended | Increase | |||||||||||||||||||||||||||||
| June 30, | (Decrease) | June 30, | (Decrease) | |||||||||||||||||||||||||||||
| (Dollars in thousands) | 2025 | 2024 | $ | % | 2025 | 2024 | $ | % | ||||||||||||||||||||||||
| Net Income | $ | 3,217 | $ | 4,298 | $ | (1,081 | ) | (25 | ) | % | $ | 243 | $ | 2,089 | $ | (1,846 | ) | 88 | % | |||||||||||||
| Interest (income) expense, net | (440 | ) | (225 | ) | (215 | ) | 96 | % | (911 | ) | (371 | ) | (540 | ) | 146 | % | ||||||||||||||||
| Income tax expense | 1,307 | 1,776 | (469 | ) | (26 | ) | % | 210 | 1,176 | (966 | ) | (82 | ) | |||||||||||||||||||
| Depreciation and amortization | 1,659 | 1,711 | (52 | ) | (3 | ) | % | 3,385 | 3,345 | 40 | 1 | % | ||||||||||||||||||||
| Stock-based compensation | 1,939 | 1,860 | 79 | 4 | % | 4,005 | 3,899 | 106 | 3 | % | ||||||||||||||||||||||
| Executive transition costs | — | (340 | ) | 340 | (100 | ) | % | 491 | (25 | ) | 516 | N.M. | % | |||||||||||||||||||
| Adjusted EBITDA | $ | 7,682 | $ | 9,080 | $ | (1,398 | ) | (15 | ) | % | $ | 7,423 | $ | 10,113 | $ | (2,690 | ) | (27 | ) | % | ||||||||||||
The following table contains a reconciliation of net income to Adjusted EBITDA for the year ended December 31, 2024:
| Tactile Systems Technology, Inc. | ||||
| Reconciliation of Net income to Non-GAAP Adjusted EBITDA | ||||
| (Unaudited) | ||||
| Year Ended | ||||
| (Dollars in thousands) | December 31, 2024 | |||
| Net income | $ | 16,960 | ||
| Interest (income) expense, net | (1,299 | ) | ||
| Income tax expense | 6,529 | |||
| Depreciation and amortization | 6,793 | |||
| Stock-based compensation | 7,819 | |||
| Executive transition costs | 248 | |||
| Adjusted EBITDA | $ | 37,050 | ||
The following table contains a reconciliation of GAAP net income guidance range to the Adjusted EBITDA guidance range for the twelve months ended December 31, 2025:
| Tactile Systems Technology, Inc. | ||||||||
| Reconciliation of FY 2025 GAAP Net Income to Adjusted EBITDA Guidance | ||||||||
| (Unaudited) | ||||||||
| Twelve Months Ended | ||||||||
| December 31, 2025 | ||||||||
| (Dollars in thousands) | Low | High | ||||||
| Net income | $ | 14,200 | $ | 15,600 | ||||
| Interest income, net | (1,800 | ) | (1,800 | ) | ||||
| Income tax expense | 5,400 | 6,000 | ||||||
| Depreciation and amortization | 6,600 | 6,600 | ||||||
| Stock-based compensation | 8,100 | 8,100 | ||||||
| Executive transition costs | 500 | 500 | ||||||
| Adjusted EBITDA | $ | 33,000 | $ | 35,000 | ||||
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com
FAQ
What were TCMD's Q2 2025 earnings results?
What is Tactile Systems' revenue guidance for 2025?
How much did TCMD's airway clearance product sales grow in Q2 2025?
How much stock did TCMD repurchase in Q2 2025?
What was TCMD's cash position as of June 30, 2025?
